Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

OPNT

Opiant Pharmaceuticals (OPNT)

Opiant Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:OPNT
DatumZeitQuelleÜberschriftSymbolFirma
03/05/202214h00GlobeNewswire Inc.Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022NASDAQ:OPNTOpiant Pharmaceuticals Inc
29/04/202218h49PR Newswire (US)Opiant Pharmaceuticals Issues Statement in Response to Fake Press ReleaseNASDAQ:OPNTOpiant Pharmaceuticals Inc
29/04/202218h47PR Newswire (US)Opiant Pharmaceuticals Issues Statement in Response to Fake Press ReleaseNASDAQ:OPNTOpiant Pharmaceuticals Inc
27/04/202222h01GlobeNewswire Inc.Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal NaloxoneNASDAQ:OPNTOpiant Pharmaceuticals Inc
18/04/202222h07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
17/03/202221h02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:OPNTOpiant Pharmaceuticals Inc
15/03/202221h10Edgar (US Regulatory)Annual Report (10-k)NASDAQ:OPNTOpiant Pharmaceuticals Inc
15/03/202221h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate UpdateNASDAQ:OPNTOpiant Pharmaceuticals Inc
10/03/202222h01GlobeNewswire Inc.Opiant Pharmaceuticals to Participate in 32nd Oppenheimer Healthcare ConferenceNASDAQ:OPNTOpiant Pharmaceuticals Inc
07/03/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022NASDAQ:OPNTOpiant Pharmaceuticals Inc
11/02/202215h33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
10/02/202214h00GlobeNewswire Inc.Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal NalmefeneNASDAQ:OPNTOpiant Pharmaceuticals Inc
27/01/202222h04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
27/01/202216h17Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
24/01/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development ProgramNASDAQ:OPNTOpiant Pharmaceuticals Inc
20/01/202223h48GlobeNewswire Inc.Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use DisorderNASDAQ:OPNTOpiant Pharmaceuticals Inc
20/01/202223h45GlobeNewswire Inc.Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release TodayNASDAQ:OPNTOpiant Pharmaceuticals Inc
20/01/202222h05GlobeNewswire Inc.Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
12/01/202222h38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
12/01/202222h29Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
05/01/202222h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
05/01/202222h22Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
05/01/202222h20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
05/01/202222h19Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
05/01/202222h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
20/12/202122h05GlobeNewswire Inc.Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
13/12/202122h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OPNTOpiant Pharmaceuticals Inc
12/11/202114h08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:OPNTOpiant Pharmaceuticals Inc
12/11/202114h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OPNTOpiant Pharmaceuticals Inc
11/11/202122h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateNASDAQ:OPNTOpiant Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:OPNT

Kürzlich von Ihnen besucht

Delayed Upgrade Clock